Distinct Regulation of EZH2 and its Repressive H3K27me3 Mark in Polyomavirus-Positive and -Negative Merkel Cell Carcinoma
Marie-Alice Durand
(1)
,
Aurélie Drouin
(1)
,
Alice Mouchard
(2, 1)
,
Laurine Durand
(1)
,
Clara Esnault
(1)
,
Patricia Berthon
(1)
,
Anne Tallet
(3)
,
Yannick Le Corre
(4)
,
Ewa Hainaut-Wierzbicka
(5)
,
Astrid Blom
(6)
,
Philippe Saiag
(6)
,
Nathalie Beneton
(7)
,
Guido Bens
(8)
,
Charlee Nardin
(9)
,
François Aubin
(9)
,
Monica Dinulescu
(10)
,
Christine Collin
(3)
,
Gaëlle Fromont-Hankard
(3)
,
Bernard Cribier
(11)
,
Sara Laurent-Roussel
(12)
,
Kristof Cokelaere
(13)
,
Roland Houben
(14)
,
David Schrama
(14)
,
Paul Peixoto
(15, 16)
,
Eric Hervouet
(15, 16)
,
Kamel Bachiri
(17)
,
Diala Kantar
(17)
,
Etienne Coyaud
(17)
,
Serge Guyétant
(18, 1)
,
Mahtab Samimi
(2, 1)
,
Antoine Touzé
(1)
,
Thibault Kervarrec
(1, 18)
1
UMR ISP -
Infectiologie et Santé Publique
2 Service de dermatologie (CHRU de Tours)
3 CHRU Tours - Centre Hospitalier Régional Universitaire de Tours
4 CHU Angers - Centre Hospitalier Universitaire d'Angers
5 CHU Poitiers - Centre hospitalier universitaire de Poitiers
6 Hôpital Ambroise Paré [AP-HP]
7 Service de dermatologie [CH Le Mans]
8 CHRO - Centre Hospitalier Régional d'Orléans
9 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
10 Centre Hospitalier Universitaire [Rennes]
11 CHU Strasbourg
12 Centre de Dermatopathologie de la Roquette
13 Jan Yperman Hospital
14 University Hospital of Würzburg
15 RIGHT - Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098)
16 EPIGENExp - EPIgenetics and GENe EXPression Technical Plateform
17 PRISM - Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192
18 Service de Pathologie [CHRU Tours]
2 Service de dermatologie (CHRU de Tours)
3 CHRU Tours - Centre Hospitalier Régional Universitaire de Tours
4 CHU Angers - Centre Hospitalier Universitaire d'Angers
5 CHU Poitiers - Centre hospitalier universitaire de Poitiers
6 Hôpital Ambroise Paré [AP-HP]
7 Service de dermatologie [CH Le Mans]
8 CHRO - Centre Hospitalier Régional d'Orléans
9 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
10 Centre Hospitalier Universitaire [Rennes]
11 CHU Strasbourg
12 Centre de Dermatopathologie de la Roquette
13 Jan Yperman Hospital
14 University Hospital of Würzburg
15 RIGHT - Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098)
16 EPIGENExp - EPIgenetics and GENe EXPression Technical Plateform
17 PRISM - Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192
18 Service de Pathologie [CHRU Tours]
Marie-Alice Durand
- Function : Author
- PersonId : 1272974
- ORCID : 0000-0002-8159-7296
Aurélie Drouin
- Function : Author
- PersonId : 1272975
- ORCID : 0000-0003-1004-9513
Alice Mouchard
- Function : Author
- PersonId : 1272976
- ORCID : 0000-0002-4143-0766
Laurine Durand
- Function : Author
- PersonId : 1272977
- ORCID : 0000-0002-7824-9952
Clara Esnault
- Function : Author
- PersonId : 755369
- ORCID : 0000-0003-4216-5711
Patricia Berthon
- Function : Author
- PersonId : 737332
- IdHAL : patricia-berthon
- ORCID : 0000-0002-3491-7613
- IdRef : 253130743
Anne Tallet
- Function : Author
- PersonId : 784676
- ORCID : 0000-0002-2601-2443
Yannick Le Corre
- Function : Author
- PersonId : 777129
- ORCID : 0000-0003-3089-3068
Ewa Hainaut-Wierzbicka
- Function : Author
- PersonId : 800737
- ORCID : 0000-0002-6475-4018
Astrid Blom
- Function : Author
- PersonId : 797027
- ORCID : 0000-0002-2848-3724
Philippe Saiag
- Function : Author
- PersonId : 1184710
- ORCID : 0000-0002-6500-3507
Nathalie Beneton
- Function : Author
- PersonId : 811912
- ORCID : 0000-0002-3052-2366
Charlee Nardin
- Function : Author
- PersonId : 800408
- ORCID : 0000-0002-9902-5990
François Aubin
- Function : Author
- PersonId : 757042
- ORCID : 0000-0002-1421-4996
Monica Dinulescu
- Function : Author
- PersonId : 781815
- ORCID : 0000-0002-3950-4340
Christine Collin
- Function : Author
- PersonId : 1272978
- ORCID : 0000-0002-7930-1855
Gaëlle Fromont-Hankard
- Function : Author
- PersonId : 761945
- ORCID : 0000-0002-7730-2264
Sara Laurent-Roussel
- Function : Author
- PersonId : 1272980
- ORCID : 0000-0003-0558-6680
Kristof Cokelaere
- Function : Author
- PersonId : 1272981
- ORCID : 0000-0001-7608-9193
Roland Houben
- Function : Author
- PersonId : 774508
- ORCID : 0000-0003-4538-2324
David Schrama
- Function : Author
- PersonId : 800736
- ORCID : 0000-0002-6931-8194
Paul Peixoto
- Function : Author
- PersonId : 760306
- ORCID : 0000-0001-6302-7823
Eric Hervouet
- Function : Author
- PersonId : 766911
- ORCID : 0000-0002-4841-7812
- IdRef : 121171140
Kamel Bachiri
- Function : Author
- PersonId : 1272982
- ORCID : 0000-0003-0297-0521
Diala Kantar
- Function : Author
- PersonId : 1152117
- ORCID : 0000-0001-9723-7204
Etienne Coyaud
- Function : Author
- PersonId : 1180207
- ORCID : 0000-0002-5893-4557
Serge Guyétant
- Function : Author
- PersonId : 1143319
- IdHAL : serge-guyetant
- ORCID : 0000-0003-2783-9722
- IdRef : 092156630
Mahtab Samimi
- Function : Author
- PersonId : 1146016
- ORCID : 0000-0001-6742-9088
- IdRef : 138889899
Antoine Touzé
- Function : Author
- PersonId : 762686
- ORCID : 0000-0002-9856-9945
- IdRef : 12461258X
Thibault Kervarrec
Connectez-vous pour contacter l'auteur
- Function : Correspondent author
- PersonId : 1078201
Connectez-vous pour contacter l'auteur
Abstract
Merkel cell carcinoma (MCC) is an aggressive skin cancer for which Merkel cell polyomavirus integration and expression of viral oncogenes small T and Large T have been identified as major oncogenic determinants. Recently, a component of the PRC2 complex, the histone methyltransferase enhancer of zeste homolog 2 (EZH2) that induces H3K27 trimethylation as a repressive mark has been proposed as a potential therapeutic target in MCC. Because divergent results have been reported for the levels of EZH2 and trimethylation of lysine 27 on histone 3, we analyzed these factors in a large MCC cohort to identify the molecular determinants of EZH2 activity in MCC and to establish MCC cell lines' sensitivity to EZH2 inhibitors. Immunohistochemical expression of EZH2 was observed in 92% of MCC tumors (156 of 170), with higher expression levels in virus-positive than virus-negative tumors (P = 0.026). For the latter, we showed overexpression of EZHIP, a negative regulator of the PRC2 complex. In vitro, ectopic expression of the large T antigen in fibroblasts led to the induction of EZH2 expression, whereas the knockdown of T antigens in MCC cell lines resulted in decreased EZH2 expression. EZH2 inhibition led to selective cytotoxicity on virus-positive MCC cell lines. This study highlights the distinct mechanisms of EZH2 induction between virus-negative and -positive MCC.